pcdna3 1 v5 Search Results


92
Addgene inc pcdna3 1 v5
Pcdna3 1 V5, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcdna3 1 v5/product/Addgene inc
Average 92 stars, based on 1 article reviews
pcdna3 1 v5 - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier

85
Addgene inc w el deiry
W El Deiry, supplied by Addgene inc, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/w el deiry/product/Addgene inc
Average 85 stars, based on 1 article reviews
w el deiry - by Bioz Stars, 2026-02
85/100 stars
  Buy from Supplier

86
Addgene inc henry lester
Henry Lester, supplied by Addgene inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/henry lester/product/Addgene inc
Average 86 stars, based on 1 article reviews
henry lester - by Bioz Stars, 2026-02
86/100 stars
  Buy from Supplier

93
Addgene inc pcdna3 1 3xflag v5 ccdb
Pcdna3 1 3xflag V5 Ccdb, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcdna3 1 3xflag v5 ccdb/product/Addgene inc
Average 93 stars, based on 1 article reviews
pcdna3 1 3xflag v5 ccdb - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

93
Addgene inc v5 tags
V5 Tags, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/v5 tags/product/Addgene inc
Average 93 stars, based on 1 article reviews
v5 tags - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

90
Addgene inc pcdna3 1 mrho v5 mer hor47a
OR cotransfection via a bidirectional expression vector in HEK293 cells. ( a,b ) Examples of calcium imaging experiments with HEK293 cells cotransfected with the <t>R.E.hOr47a</t> + Orco constructs in 2 <t>different</t> <t>pcDNA3.1(-)</t> vectors (a) and with the pDmelOR-R.E.hOr47a housing both the hOr47a and a codon-optimized version of Orco (hOrco) bearing the β-globin/IgG chimeric intron (c.i.) (b). Panels represent—from left to right—a schematic representation of the constructs tested; transmission light image of the tested HEK293 cells; base level [Ca 2+ ] i of transfected HEK293 cells (0 s); [Ca 2+ ] i 25 s after application of 100 µL of 100 µM pentyl acetate (75 s) and 25 s after application of 100 µL of 100 µM VUAA1 (375 s). Scale bar = 50 µm. ( c ) Changes in intracellular calcium concentration over time (Δ[Ca 2+ ] i ) in HEK293 cells transfected with the construct shown in panels (a-b), following stimulations with 100 µL of 100 µM of the Or47a agonist pentyl acetate (PA) at 50 s and the synthetic Orco agonist VUAA1 at 350 s. Graphs represent mean ± SD. n = 5 for R.E.hOr47a + Orco and n = 3 for pDmelOR-R.E.hOr47a. Each n = 1 represents the mean of all imaged cells coming from independently electroporated cuvettes (see Methods). ( d ) Intensity of calcium responses following a pentyl acetate or a VUAA1 stimulation in cells transfected with the constructs described in panels (a–b). Δ[Ca 2+ ] i values were extracted 50 s after a stimulation with 100 µL of 100 µM pentyl acetate, and 20 s after a stimulation with 100 µL of 100 µM VUAA1. Mean ± SD values for pentyl acetate: R.E.hOr47a + Orco, 6.89 ± 1.41; pDmelOR-R.E.hOr47a, 38.43 ± 6.04. Statistical analysis for pentyl acetate: pDmelOR-R.E.hOr47a versus R.E.hOr47a + Orco, t = 8.90, P = 0.010, Two-tailed Welch’s t test. Mean ± SD values for VUAA1: R.E.hOr47a + Orco, 61.32 ± 13.29; pDmelOR-R.E.hOr47a, 149.24 ± 20.12. Statistical analysis for VUAA1: pDmelOR-R.E.hOr47a versus R.E.hOr47a + Orco, W = 15, P = 0.036, Wilcoxon rank sum test. Graphs represent mean ± SD. n = 5 for R.E.hOr47a + Orco and n = 3 for pDmelOR-R.E.hOr47a. ( e ) Percentage of responding ROIs following a pentyl acetate or a VUAA1 stimulation. Mean ± SD values for pentyl acetate: R.E.hOr47a + Orco, 30.51 ± 6.56; pDmelOR-R.E.hOr47a, 76.01± 10.64. Statistical analysis for pentyl acetate: pDmelOR-R.E.hOr47a versus R.E.hOr47a + Orco: t = 6.68, P = 0.0073. Mean ± SD values for VUAA1: R.E.hOr47a + Orco, 71.76 ± 3.29; pDmelOR-R.E.hOr47a, 92.47± 4.03. Statistical analysis for VUAA1: pDmelOR-R.E.hOr47a versus R.E.hOr47a + Orco: t = 7.52, P = 0.0024. Two-tailed Welch’s t tests. Graphs represent mean ± SD. n = 5 for R.E.hOr47a + Orco and n = 3 for pDmelOR-R.E.hOr47a.
Pcdna3 1 Mrho V5 Mer Hor47a, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcdna3 1 mrho v5 mer hor47a/product/Addgene inc
Average 90 stars, based on 1 article reviews
pcdna3 1 mrho v5 mer hor47a - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Addgene inc tev protease
OR cotransfection via a bidirectional expression vector in HEK293 cells. ( a,b ) Examples of calcium imaging experiments with HEK293 cells cotransfected with the <t>R.E.hOr47a</t> + Orco constructs in 2 <t>different</t> <t>pcDNA3.1(-)</t> vectors (a) and with the pDmelOR-R.E.hOr47a housing both the hOr47a and a codon-optimized version of Orco (hOrco) bearing the β-globin/IgG chimeric intron (c.i.) (b). Panels represent—from left to right—a schematic representation of the constructs tested; transmission light image of the tested HEK293 cells; base level [Ca 2+ ] i of transfected HEK293 cells (0 s); [Ca 2+ ] i 25 s after application of 100 µL of 100 µM pentyl acetate (75 s) and 25 s after application of 100 µL of 100 µM VUAA1 (375 s). Scale bar = 50 µm. ( c ) Changes in intracellular calcium concentration over time (Δ[Ca 2+ ] i ) in HEK293 cells transfected with the construct shown in panels (a-b), following stimulations with 100 µL of 100 µM of the Or47a agonist pentyl acetate (PA) at 50 s and the synthetic Orco agonist VUAA1 at 350 s. Graphs represent mean ± SD. n = 5 for R.E.hOr47a + Orco and n = 3 for pDmelOR-R.E.hOr47a. Each n = 1 represents the mean of all imaged cells coming from independently electroporated cuvettes (see Methods). ( d ) Intensity of calcium responses following a pentyl acetate or a VUAA1 stimulation in cells transfected with the constructs described in panels (a–b). Δ[Ca 2+ ] i values were extracted 50 s after a stimulation with 100 µL of 100 µM pentyl acetate, and 20 s after a stimulation with 100 µL of 100 µM VUAA1. Mean ± SD values for pentyl acetate: R.E.hOr47a + Orco, 6.89 ± 1.41; pDmelOR-R.E.hOr47a, 38.43 ± 6.04. Statistical analysis for pentyl acetate: pDmelOR-R.E.hOr47a versus R.E.hOr47a + Orco, t = 8.90, P = 0.010, Two-tailed Welch’s t test. Mean ± SD values for VUAA1: R.E.hOr47a + Orco, 61.32 ± 13.29; pDmelOR-R.E.hOr47a, 149.24 ± 20.12. Statistical analysis for VUAA1: pDmelOR-R.E.hOr47a versus R.E.hOr47a + Orco, W = 15, P = 0.036, Wilcoxon rank sum test. Graphs represent mean ± SD. n = 5 for R.E.hOr47a + Orco and n = 3 for pDmelOR-R.E.hOr47a. ( e ) Percentage of responding ROIs following a pentyl acetate or a VUAA1 stimulation. Mean ± SD values for pentyl acetate: R.E.hOr47a + Orco, 30.51 ± 6.56; pDmelOR-R.E.hOr47a, 76.01± 10.64. Statistical analysis for pentyl acetate: pDmelOR-R.E.hOr47a versus R.E.hOr47a + Orco: t = 6.68, P = 0.0073. Mean ± SD values for VUAA1: R.E.hOr47a + Orco, 71.76 ± 3.29; pDmelOR-R.E.hOr47a, 92.47± 4.03. Statistical analysis for VUAA1: pDmelOR-R.E.hOr47a versus R.E.hOr47a + Orco: t = 7.52, P = 0.0024. Two-tailed Welch’s t tests. Graphs represent mean ± SD. n = 5 for R.E.hOr47a + Orco and n = 3 for pDmelOR-R.E.hOr47a.
Tev Protease, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tev protease/product/Addgene inc
Average 90 stars, based on 1 article reviews
tev protease - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Addgene inc pcdna3 1 v5 mer hor47a
(a) The human HCN1 receptor sequence 106 VNKFSL 111 encoding a minimal endoplasmic reticulum release signal (two pcDNA3.1(-) plasmid constructs. The first, with the insertion of a human codon-optimized version of the D. melanogaster Or47a (hOr47a) tagged at the N-terminus with: a peptide composed of the mRho, mER and a V5 tag – to detect the receptor via immunochemistry if necessary – (R.E.hOr47a construct), or tagged only with the mER and V5 peptides (E.hOr47a) or the V5 tag alone (hOr47a). The second construct was constituted by a non codon-optimized version of D. melanogaster Orco co-receptor. As controls, cells were co-transfected with the Orco co-receptor together with the empty vector backbone (EV) instead of the hOr47a construct, or with the empty vector alone. (c) Changes in intracellular calcium concentration over time (Δ[Ca 2+ ] i ) in HEK293 cells transfected with the constructs shown in panel (b), following stimulations with 100 µl of 100 µM of the Or47a agonist pentyl acetate (PA) at 50 s and the synthetic Orco agonist VUAA1 at 350 s. Graphs represent mean ± SD. n = 5 for each panel. Each n = 1 represents the mean of all imaged cells coming from each independent electroporated cuvette (see Methods). (d) Intensity of calcium responses following a pentyl acetate or a VUAA1 stimulation in cells transfected with the constructs described in panel (b). Values were extracted 50 s after a stimulation with 100 µl of 100 µM pentyl acetate, and 20 s after a stimulation with 100 µl of 100 µM VUAA1. Mean ± SD values for pentyl acetate: EV, −0.07 ± 0.63; Orco, 0.11 ± 0.64; hOr47a + Orco, 0.35 ± 0.61; E.hOr47a + Orco, 4.44 ± 0.66; R.E.hOr47a + Orco, 6.89 ± 1.41. Statistical analysis for pentyl acetate: R.E.hOr47a + Orco versus (vs.) E.hOr47a + Orco: t = 3.52, p = 0.014; R.E.hOr47a + Orco vs. hOr47a + Orco: t = 9.52, p < 0.001; R.E.hOr47a + Orco vs. Orco: t = 9.81, p < 0.001. Mean ± SD values for VUAA1: EV, −0.68 ± 0.24; Orco, 9.52 ± 4.11; hOr47a + Orco, 15.88 ± 5.29; E.hOr47a + Orco, 45.02 ± 7.02; R.E.hOr47a + Orco, 61.32 ± 13.29. Statistical analysis for VUAA1: R.E.hOr47a + Orco versus (vs.) E.hOr47a + Orco: t = 2.42, p = 0.051; R.E.hOr47a + Orco vs. hOr47a + Orco: t = 7.10, p = 0.0015; R.E.hOr47a + Orco vs. Orco: t = 8.32, p = 0.0015. (e) Percentage of responding ROIs following a pentyl acetate or a VUAA1 stimulation. Mean ± SD values for pentyl acetate: EV, 0.18 ± 0.16; Orco, 0.64 ± 0.50; hOr47a + Orco, 2.90 ± 1.05; E.hOr47a + Orco, 21.61 ± 4.16; R.E.hOr47a + Orco, 30.51 ± 6.56. Statistical analysis for pentyl acetate: R.E.hOr47a + Orco versus (vs.) E.hOr47a + Orco: t = 2.56, p = 0.039; R.E.hOr47a + Orco vs. hOr47a + Orco: t = 9.29, p = 0.0015; R.E.hOr47a + Orco vs. Orco: t = 10.16, p = 0.0015. Mean ± SD values for VUAA1: EV, 0.06 ± 0.14; Orco, 24.12 ± 9.10; hOr47a + Orco, 30.24 ± 7.21; E.hOr47a + Orco, 61.49± 5.95; R.E.hOr47a + Orco, 71.76 ± 3.29. Statistical analysis for VUAA1: R.E.hOr47a + Orco versus (vs.) E.hOr47a + Orco: t = 3.38, p = 0.015; R.E.hOr47a + Orco vs. hOr47a + Orco: t = 11.71, p < 0.001; R.E.hOr47a + Orco vs. Orco: W = 25, p = 0.016 (Wilcoxon rank test). Unless otherwise stated, tests are unpaired two-tails Welch’t t-test. P values corrected for multiple comparisons using Holm’s correction. Bar plots represent mean ± SD, n = 5 for each treatment. * p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant. " width="250" height="auto" />
Pcdna3 1 V5 Mer Hor47a, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcdna3 1 v5 mer hor47a/product/Addgene inc
Average 90 stars, based on 1 article reviews
pcdna3 1 v5 mer hor47a - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

92
Addgene inc plasmids encoding v5 pyk2
(a) The human HCN1 receptor sequence 106 VNKFSL 111 encoding a minimal endoplasmic reticulum release signal (two pcDNA3.1(-) plasmid constructs. The first, with the insertion of a human codon-optimized version of the D. melanogaster Or47a (hOr47a) tagged at the N-terminus with: a peptide composed of the mRho, mER and a V5 tag – to detect the receptor via immunochemistry if necessary – (R.E.hOr47a construct), or tagged only with the mER and V5 peptides (E.hOr47a) or the V5 tag alone (hOr47a). The second construct was constituted by a non codon-optimized version of D. melanogaster Orco co-receptor. As controls, cells were co-transfected with the Orco co-receptor together with the empty vector backbone (EV) instead of the hOr47a construct, or with the empty vector alone. (c) Changes in intracellular calcium concentration over time (Δ[Ca 2+ ] i ) in HEK293 cells transfected with the constructs shown in panel (b), following stimulations with 100 µl of 100 µM of the Or47a agonist pentyl acetate (PA) at 50 s and the synthetic Orco agonist VUAA1 at 350 s. Graphs represent mean ± SD. n = 5 for each panel. Each n = 1 represents the mean of all imaged cells coming from each independent electroporated cuvette (see Methods). (d) Intensity of calcium responses following a pentyl acetate or a VUAA1 stimulation in cells transfected with the constructs described in panel (b). Values were extracted 50 s after a stimulation with 100 µl of 100 µM pentyl acetate, and 20 s after a stimulation with 100 µl of 100 µM VUAA1. Mean ± SD values for pentyl acetate: EV, −0.07 ± 0.63; Orco, 0.11 ± 0.64; hOr47a + Orco, 0.35 ± 0.61; E.hOr47a + Orco, 4.44 ± 0.66; R.E.hOr47a + Orco, 6.89 ± 1.41. Statistical analysis for pentyl acetate: R.E.hOr47a + Orco versus (vs.) E.hOr47a + Orco: t = 3.52, p = 0.014; R.E.hOr47a + Orco vs. hOr47a + Orco: t = 9.52, p < 0.001; R.E.hOr47a + Orco vs. Orco: t = 9.81, p < 0.001. Mean ± SD values for VUAA1: EV, −0.68 ± 0.24; Orco, 9.52 ± 4.11; hOr47a + Orco, 15.88 ± 5.29; E.hOr47a + Orco, 45.02 ± 7.02; R.E.hOr47a + Orco, 61.32 ± 13.29. Statistical analysis for VUAA1: R.E.hOr47a + Orco versus (vs.) E.hOr47a + Orco: t = 2.42, p = 0.051; R.E.hOr47a + Orco vs. hOr47a + Orco: t = 7.10, p = 0.0015; R.E.hOr47a + Orco vs. Orco: t = 8.32, p = 0.0015. (e) Percentage of responding ROIs following a pentyl acetate or a VUAA1 stimulation. Mean ± SD values for pentyl acetate: EV, 0.18 ± 0.16; Orco, 0.64 ± 0.50; hOr47a + Orco, 2.90 ± 1.05; E.hOr47a + Orco, 21.61 ± 4.16; R.E.hOr47a + Orco, 30.51 ± 6.56. Statistical analysis for pentyl acetate: R.E.hOr47a + Orco versus (vs.) E.hOr47a + Orco: t = 2.56, p = 0.039; R.E.hOr47a + Orco vs. hOr47a + Orco: t = 9.29, p = 0.0015; R.E.hOr47a + Orco vs. Orco: t = 10.16, p = 0.0015. Mean ± SD values for VUAA1: EV, 0.06 ± 0.14; Orco, 24.12 ± 9.10; hOr47a + Orco, 30.24 ± 7.21; E.hOr47a + Orco, 61.49± 5.95; R.E.hOr47a + Orco, 71.76 ± 3.29. Statistical analysis for VUAA1: R.E.hOr47a + Orco versus (vs.) E.hOr47a + Orco: t = 3.38, p = 0.015; R.E.hOr47a + Orco vs. hOr47a + Orco: t = 11.71, p < 0.001; R.E.hOr47a + Orco vs. Orco: W = 25, p = 0.016 (Wilcoxon rank test). Unless otherwise stated, tests are unpaired two-tails Welch’t t-test. P values corrected for multiple comparisons using Holm’s correction. Bar plots represent mean ± SD, n = 5 for each treatment. * p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant. " width="250" height="auto" />
Plasmids Encoding V5 Pyk2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/plasmids encoding v5 pyk2/product/Addgene inc
Average 92 stars, based on 1 article reviews
plasmids encoding v5 pyk2 - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier

92
Addgene inc amino acids 1 44
(a) The human HCN1 receptor sequence 106 VNKFSL 111 encoding a minimal endoplasmic reticulum release signal (two pcDNA3.1(-) plasmid constructs. The first, with the insertion of a human codon-optimized version of the D. melanogaster Or47a (hOr47a) tagged at the N-terminus with: a peptide composed of the mRho, mER and a V5 tag – to detect the receptor via immunochemistry if necessary – (R.E.hOr47a construct), or tagged only with the mER and V5 peptides (E.hOr47a) or the V5 tag alone (hOr47a). The second construct was constituted by a non codon-optimized version of D. melanogaster Orco co-receptor. As controls, cells were co-transfected with the Orco co-receptor together with the empty vector backbone (EV) instead of the hOr47a construct, or with the empty vector alone. (c) Changes in intracellular calcium concentration over time (Δ[Ca 2+ ] i ) in HEK293 cells transfected with the constructs shown in panel (b), following stimulations with 100 µl of 100 µM of the Or47a agonist pentyl acetate (PA) at 50 s and the synthetic Orco agonist VUAA1 at 350 s. Graphs represent mean ± SD. n = 5 for each panel. Each n = 1 represents the mean of all imaged cells coming from each independent electroporated cuvette (see Methods). (d) Intensity of calcium responses following a pentyl acetate or a VUAA1 stimulation in cells transfected with the constructs described in panel (b). Values were extracted 50 s after a stimulation with 100 µl of 100 µM pentyl acetate, and 20 s after a stimulation with 100 µl of 100 µM VUAA1. Mean ± SD values for pentyl acetate: EV, −0.07 ± 0.63; Orco, 0.11 ± 0.64; hOr47a + Orco, 0.35 ± 0.61; E.hOr47a + Orco, 4.44 ± 0.66; R.E.hOr47a + Orco, 6.89 ± 1.41. Statistical analysis for pentyl acetate: R.E.hOr47a + Orco versus (vs.) E.hOr47a + Orco: t = 3.52, p = 0.014; R.E.hOr47a + Orco vs. hOr47a + Orco: t = 9.52, p < 0.001; R.E.hOr47a + Orco vs. Orco: t = 9.81, p < 0.001. Mean ± SD values for VUAA1: EV, −0.68 ± 0.24; Orco, 9.52 ± 4.11; hOr47a + Orco, 15.88 ± 5.29; E.hOr47a + Orco, 45.02 ± 7.02; R.E.hOr47a + Orco, 61.32 ± 13.29. Statistical analysis for VUAA1: R.E.hOr47a + Orco versus (vs.) E.hOr47a + Orco: t = 2.42, p = 0.051; R.E.hOr47a + Orco vs. hOr47a + Orco: t = 7.10, p = 0.0015; R.E.hOr47a + Orco vs. Orco: t = 8.32, p = 0.0015. (e) Percentage of responding ROIs following a pentyl acetate or a VUAA1 stimulation. Mean ± SD values for pentyl acetate: EV, 0.18 ± 0.16; Orco, 0.64 ± 0.50; hOr47a + Orco, 2.90 ± 1.05; E.hOr47a + Orco, 21.61 ± 4.16; R.E.hOr47a + Orco, 30.51 ± 6.56. Statistical analysis for pentyl acetate: R.E.hOr47a + Orco versus (vs.) E.hOr47a + Orco: t = 2.56, p = 0.039; R.E.hOr47a + Orco vs. hOr47a + Orco: t = 9.29, p = 0.0015; R.E.hOr47a + Orco vs. Orco: t = 10.16, p = 0.0015. Mean ± SD values for VUAA1: EV, 0.06 ± 0.14; Orco, 24.12 ± 9.10; hOr47a + Orco, 30.24 ± 7.21; E.hOr47a + Orco, 61.49± 5.95; R.E.hOr47a + Orco, 71.76 ± 3.29. Statistical analysis for VUAA1: R.E.hOr47a + Orco versus (vs.) E.hOr47a + Orco: t = 3.38, p = 0.015; R.E.hOr47a + Orco vs. hOr47a + Orco: t = 11.71, p < 0.001; R.E.hOr47a + Orco vs. Orco: W = 25, p = 0.016 (Wilcoxon rank test). Unless otherwise stated, tests are unpaired two-tails Welch’t t-test. P values corrected for multiple comparisons using Holm’s correction. Bar plots represent mean ± SD, n = 5 for each treatment. * p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant. " width="250" height="auto" />
Amino Acids 1 44, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/amino acids 1 44/product/Addgene inc
Average 92 stars, based on 1 article reviews
amino acids 1 44 - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier

93
Addgene inc pcdna3 1 v5 his topo mir 17 92
(a) The human HCN1 receptor sequence 106 VNKFSL 111 encoding a minimal endoplasmic reticulum release signal (two pcDNA3.1(-) plasmid constructs. The first, with the insertion of a human codon-optimized version of the D. melanogaster Or47a (hOr47a) tagged at the N-terminus with: a peptide composed of the mRho, mER and a V5 tag – to detect the receptor via immunochemistry if necessary – (R.E.hOr47a construct), or tagged only with the mER and V5 peptides (E.hOr47a) or the V5 tag alone (hOr47a). The second construct was constituted by a non codon-optimized version of D. melanogaster Orco co-receptor. As controls, cells were co-transfected with the Orco co-receptor together with the empty vector backbone (EV) instead of the hOr47a construct, or with the empty vector alone. (c) Changes in intracellular calcium concentration over time (Δ[Ca 2+ ] i ) in HEK293 cells transfected with the constructs shown in panel (b), following stimulations with 100 µl of 100 µM of the Or47a agonist pentyl acetate (PA) at 50 s and the synthetic Orco agonist VUAA1 at 350 s. Graphs represent mean ± SD. n = 5 for each panel. Each n = 1 represents the mean of all imaged cells coming from each independent electroporated cuvette (see Methods). (d) Intensity of calcium responses following a pentyl acetate or a VUAA1 stimulation in cells transfected with the constructs described in panel (b). Values were extracted 50 s after a stimulation with 100 µl of 100 µM pentyl acetate, and 20 s after a stimulation with 100 µl of 100 µM VUAA1. Mean ± SD values for pentyl acetate: EV, −0.07 ± 0.63; Orco, 0.11 ± 0.64; hOr47a + Orco, 0.35 ± 0.61; E.hOr47a + Orco, 4.44 ± 0.66; R.E.hOr47a + Orco, 6.89 ± 1.41. Statistical analysis for pentyl acetate: R.E.hOr47a + Orco versus (vs.) E.hOr47a + Orco: t = 3.52, p = 0.014; R.E.hOr47a + Orco vs. hOr47a + Orco: t = 9.52, p < 0.001; R.E.hOr47a + Orco vs. Orco: t = 9.81, p < 0.001. Mean ± SD values for VUAA1: EV, −0.68 ± 0.24; Orco, 9.52 ± 4.11; hOr47a + Orco, 15.88 ± 5.29; E.hOr47a + Orco, 45.02 ± 7.02; R.E.hOr47a + Orco, 61.32 ± 13.29. Statistical analysis for VUAA1: R.E.hOr47a + Orco versus (vs.) E.hOr47a + Orco: t = 2.42, p = 0.051; R.E.hOr47a + Orco vs. hOr47a + Orco: t = 7.10, p = 0.0015; R.E.hOr47a + Orco vs. Orco: t = 8.32, p = 0.0015. (e) Percentage of responding ROIs following a pentyl acetate or a VUAA1 stimulation. Mean ± SD values for pentyl acetate: EV, 0.18 ± 0.16; Orco, 0.64 ± 0.50; hOr47a + Orco, 2.90 ± 1.05; E.hOr47a + Orco, 21.61 ± 4.16; R.E.hOr47a + Orco, 30.51 ± 6.56. Statistical analysis for pentyl acetate: R.E.hOr47a + Orco versus (vs.) E.hOr47a + Orco: t = 2.56, p = 0.039; R.E.hOr47a + Orco vs. hOr47a + Orco: t = 9.29, p = 0.0015; R.E.hOr47a + Orco vs. Orco: t = 10.16, p = 0.0015. Mean ± SD values for VUAA1: EV, 0.06 ± 0.14; Orco, 24.12 ± 9.10; hOr47a + Orco, 30.24 ± 7.21; E.hOr47a + Orco, 61.49± 5.95; R.E.hOr47a + Orco, 71.76 ± 3.29. Statistical analysis for VUAA1: R.E.hOr47a + Orco versus (vs.) E.hOr47a + Orco: t = 3.38, p = 0.015; R.E.hOr47a + Orco vs. hOr47a + Orco: t = 11.71, p < 0.001; R.E.hOr47a + Orco vs. Orco: W = 25, p = 0.016 (Wilcoxon rank test). Unless otherwise stated, tests are unpaired two-tails Welch’t t-test. P values corrected for multiple comparisons using Holm’s correction. Bar plots represent mean ± SD, n = 5 for each treatment. * p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant. " width="250" height="auto" />
Pcdna3 1 V5 His Topo Mir 17 92, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcdna3 1 v5 his topo mir 17 92/product/Addgene inc
Average 93 stars, based on 1 article reviews
pcdna3 1 v5 his topo mir 17 92 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

93
Addgene inc pcdna3 1 cip2a
(a) The human HCN1 receptor sequence 106 VNKFSL 111 encoding a minimal endoplasmic reticulum release signal (two pcDNA3.1(-) plasmid constructs. The first, with the insertion of a human codon-optimized version of the D. melanogaster Or47a (hOr47a) tagged at the N-terminus with: a peptide composed of the mRho, mER and a V5 tag – to detect the receptor via immunochemistry if necessary – (R.E.hOr47a construct), or tagged only with the mER and V5 peptides (E.hOr47a) or the V5 tag alone (hOr47a). The second construct was constituted by a non codon-optimized version of D. melanogaster Orco co-receptor. As controls, cells were co-transfected with the Orco co-receptor together with the empty vector backbone (EV) instead of the hOr47a construct, or with the empty vector alone. (c) Changes in intracellular calcium concentration over time (Δ[Ca 2+ ] i ) in HEK293 cells transfected with the constructs shown in panel (b), following stimulations with 100 µl of 100 µM of the Or47a agonist pentyl acetate (PA) at 50 s and the synthetic Orco agonist VUAA1 at 350 s. Graphs represent mean ± SD. n = 5 for each panel. Each n = 1 represents the mean of all imaged cells coming from each independent electroporated cuvette (see Methods). (d) Intensity of calcium responses following a pentyl acetate or a VUAA1 stimulation in cells transfected with the constructs described in panel (b). Values were extracted 50 s after a stimulation with 100 µl of 100 µM pentyl acetate, and 20 s after a stimulation with 100 µl of 100 µM VUAA1. Mean ± SD values for pentyl acetate: EV, −0.07 ± 0.63; Orco, 0.11 ± 0.64; hOr47a + Orco, 0.35 ± 0.61; E.hOr47a + Orco, 4.44 ± 0.66; R.E.hOr47a + Orco, 6.89 ± 1.41. Statistical analysis for pentyl acetate: R.E.hOr47a + Orco versus (vs.) E.hOr47a + Orco: t = 3.52, p = 0.014; R.E.hOr47a + Orco vs. hOr47a + Orco: t = 9.52, p < 0.001; R.E.hOr47a + Orco vs. Orco: t = 9.81, p < 0.001. Mean ± SD values for VUAA1: EV, −0.68 ± 0.24; Orco, 9.52 ± 4.11; hOr47a + Orco, 15.88 ± 5.29; E.hOr47a + Orco, 45.02 ± 7.02; R.E.hOr47a + Orco, 61.32 ± 13.29. Statistical analysis for VUAA1: R.E.hOr47a + Orco versus (vs.) E.hOr47a + Orco: t = 2.42, p = 0.051; R.E.hOr47a + Orco vs. hOr47a + Orco: t = 7.10, p = 0.0015; R.E.hOr47a + Orco vs. Orco: t = 8.32, p = 0.0015. (e) Percentage of responding ROIs following a pentyl acetate or a VUAA1 stimulation. Mean ± SD values for pentyl acetate: EV, 0.18 ± 0.16; Orco, 0.64 ± 0.50; hOr47a + Orco, 2.90 ± 1.05; E.hOr47a + Orco, 21.61 ± 4.16; R.E.hOr47a + Orco, 30.51 ± 6.56. Statistical analysis for pentyl acetate: R.E.hOr47a + Orco versus (vs.) E.hOr47a + Orco: t = 2.56, p = 0.039; R.E.hOr47a + Orco vs. hOr47a + Orco: t = 9.29, p = 0.0015; R.E.hOr47a + Orco vs. Orco: t = 10.16, p = 0.0015. Mean ± SD values for VUAA1: EV, 0.06 ± 0.14; Orco, 24.12 ± 9.10; hOr47a + Orco, 30.24 ± 7.21; E.hOr47a + Orco, 61.49± 5.95; R.E.hOr47a + Orco, 71.76 ± 3.29. Statistical analysis for VUAA1: R.E.hOr47a + Orco versus (vs.) E.hOr47a + Orco: t = 3.38, p = 0.015; R.E.hOr47a + Orco vs. hOr47a + Orco: t = 11.71, p < 0.001; R.E.hOr47a + Orco vs. Orco: W = 25, p = 0.016 (Wilcoxon rank test). Unless otherwise stated, tests are unpaired two-tails Welch’t t-test. P values corrected for multiple comparisons using Holm’s correction. Bar plots represent mean ± SD, n = 5 for each treatment. * p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant. " width="250" height="auto" />
Pcdna3 1 Cip2a, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcdna3 1 cip2a/product/Addgene inc
Average 93 stars, based on 1 article reviews
pcdna3 1 cip2a - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

Image Search Results


OR cotransfection via a bidirectional expression vector in HEK293 cells. ( a,b ) Examples of calcium imaging experiments with HEK293 cells cotransfected with the R.E.hOr47a + Orco constructs in 2 different pcDNA3.1(-) vectors (a) and with the pDmelOR-R.E.hOr47a housing both the hOr47a and a codon-optimized version of Orco (hOrco) bearing the β-globin/IgG chimeric intron (c.i.) (b). Panels represent—from left to right—a schematic representation of the constructs tested; transmission light image of the tested HEK293 cells; base level [Ca 2+ ] i of transfected HEK293 cells (0 s); [Ca 2+ ] i 25 s after application of 100 µL of 100 µM pentyl acetate (75 s) and 25 s after application of 100 µL of 100 µM VUAA1 (375 s). Scale bar = 50 µm. ( c ) Changes in intracellular calcium concentration over time (Δ[Ca 2+ ] i ) in HEK293 cells transfected with the construct shown in panels (a-b), following stimulations with 100 µL of 100 µM of the Or47a agonist pentyl acetate (PA) at 50 s and the synthetic Orco agonist VUAA1 at 350 s. Graphs represent mean ± SD. n = 5 for R.E.hOr47a + Orco and n = 3 for pDmelOR-R.E.hOr47a. Each n = 1 represents the mean of all imaged cells coming from independently electroporated cuvettes (see Methods). ( d ) Intensity of calcium responses following a pentyl acetate or a VUAA1 stimulation in cells transfected with the constructs described in panels (a–b). Δ[Ca 2+ ] i values were extracted 50 s after a stimulation with 100 µL of 100 µM pentyl acetate, and 20 s after a stimulation with 100 µL of 100 µM VUAA1. Mean ± SD values for pentyl acetate: R.E.hOr47a + Orco, 6.89 ± 1.41; pDmelOR-R.E.hOr47a, 38.43 ± 6.04. Statistical analysis for pentyl acetate: pDmelOR-R.E.hOr47a versus R.E.hOr47a + Orco, t = 8.90, P = 0.010, Two-tailed Welch’s t test. Mean ± SD values for VUAA1: R.E.hOr47a + Orco, 61.32 ± 13.29; pDmelOR-R.E.hOr47a, 149.24 ± 20.12. Statistical analysis for VUAA1: pDmelOR-R.E.hOr47a versus R.E.hOr47a + Orco, W = 15, P = 0.036, Wilcoxon rank sum test. Graphs represent mean ± SD. n = 5 for R.E.hOr47a + Orco and n = 3 for pDmelOR-R.E.hOr47a. ( e ) Percentage of responding ROIs following a pentyl acetate or a VUAA1 stimulation. Mean ± SD values for pentyl acetate: R.E.hOr47a + Orco, 30.51 ± 6.56; pDmelOR-R.E.hOr47a, 76.01± 10.64. Statistical analysis for pentyl acetate: pDmelOR-R.E.hOr47a versus R.E.hOr47a + Orco: t = 6.68, P = 0.0073. Mean ± SD values for VUAA1: R.E.hOr47a + Orco, 71.76 ± 3.29; pDmelOR-R.E.hOr47a, 92.47± 4.03. Statistical analysis for VUAA1: pDmelOR-R.E.hOr47a versus R.E.hOr47a + Orco: t = 7.52, P = 0.0024. Two-tailed Welch’s t tests. Graphs represent mean ± SD. n = 5 for R.E.hOr47a + Orco and n = 3 for pDmelOR-R.E.hOr47a.

Journal: Chemical Senses

Article Title: Optimization of Insect Odorant Receptor Trafficking and Functional Expression Via Transient Transfection in HEK293 Cells

doi: 10.1093/chemse/bjz062

Figure Lengend Snippet: OR cotransfection via a bidirectional expression vector in HEK293 cells. ( a,b ) Examples of calcium imaging experiments with HEK293 cells cotransfected with the R.E.hOr47a + Orco constructs in 2 different pcDNA3.1(-) vectors (a) and with the pDmelOR-R.E.hOr47a housing both the hOr47a and a codon-optimized version of Orco (hOrco) bearing the β-globin/IgG chimeric intron (c.i.) (b). Panels represent—from left to right—a schematic representation of the constructs tested; transmission light image of the tested HEK293 cells; base level [Ca 2+ ] i of transfected HEK293 cells (0 s); [Ca 2+ ] i 25 s after application of 100 µL of 100 µM pentyl acetate (75 s) and 25 s after application of 100 µL of 100 µM VUAA1 (375 s). Scale bar = 50 µm. ( c ) Changes in intracellular calcium concentration over time (Δ[Ca 2+ ] i ) in HEK293 cells transfected with the construct shown in panels (a-b), following stimulations with 100 µL of 100 µM of the Or47a agonist pentyl acetate (PA) at 50 s and the synthetic Orco agonist VUAA1 at 350 s. Graphs represent mean ± SD. n = 5 for R.E.hOr47a + Orco and n = 3 for pDmelOR-R.E.hOr47a. Each n = 1 represents the mean of all imaged cells coming from independently electroporated cuvettes (see Methods). ( d ) Intensity of calcium responses following a pentyl acetate or a VUAA1 stimulation in cells transfected with the constructs described in panels (a–b). Δ[Ca 2+ ] i values were extracted 50 s after a stimulation with 100 µL of 100 µM pentyl acetate, and 20 s after a stimulation with 100 µL of 100 µM VUAA1. Mean ± SD values for pentyl acetate: R.E.hOr47a + Orco, 6.89 ± 1.41; pDmelOR-R.E.hOr47a, 38.43 ± 6.04. Statistical analysis for pentyl acetate: pDmelOR-R.E.hOr47a versus R.E.hOr47a + Orco, t = 8.90, P = 0.010, Two-tailed Welch’s t test. Mean ± SD values for VUAA1: R.E.hOr47a + Orco, 61.32 ± 13.29; pDmelOR-R.E.hOr47a, 149.24 ± 20.12. Statistical analysis for VUAA1: pDmelOR-R.E.hOr47a versus R.E.hOr47a + Orco, W = 15, P = 0.036, Wilcoxon rank sum test. Graphs represent mean ± SD. n = 5 for R.E.hOr47a + Orco and n = 3 for pDmelOR-R.E.hOr47a. ( e ) Percentage of responding ROIs following a pentyl acetate or a VUAA1 stimulation. Mean ± SD values for pentyl acetate: R.E.hOr47a + Orco, 30.51 ± 6.56; pDmelOR-R.E.hOr47a, 76.01± 10.64. Statistical analysis for pentyl acetate: pDmelOR-R.E.hOr47a versus R.E.hOr47a + Orco: t = 6.68, P = 0.0073. Mean ± SD values for VUAA1: R.E.hOr47a + Orco, 71.76 ± 3.29; pDmelOR-R.E.hOr47a, 92.47± 4.03. Statistical analysis for VUAA1: pDmelOR-R.E.hOr47a versus R.E.hOr47a + Orco: t = 7.52, P = 0.0024. Two-tailed Welch’s t tests. Graphs represent mean ± SD. n = 5 for R.E.hOr47a + Orco and n = 3 for pDmelOR-R.E.hOr47a.

Article Snippet: Primer sequences are listed in the Full sequences for the reported constructs and plasmid availability information are accessible at Addgene ( https://www.addgene.org ) with the following reference numbers: pcDNA3.1(-)-mRho.V5.mER.hOr47a: #126472; pcDNA3.1(-)-V5.mER.hOr47a: #126473; pcDNA3.1(-)-V5.hOr47a: #126474; pCMV-BI: #126475; pDmelOR: #126476; pDmelOR-mRho.V5.mER.hOr47a: #126478; pDmelOR-mRho.V5.mER.hOr56a: #126479.

Techniques: Cotransfection, Expressing, Plasmid Preparation, Imaging, Construct, Transmission Assay, Transfection, Concentration Assay, Two Tailed Test

Optimization of OR trafficking to the plasma membrane in HEK293 cells. ( a ) The human HCN1 receptor sequence 106 VNKFSL 111 encoding a minimal endoplasmic reticulum release signal (“mER”, or “E”) and the human Rhodopsin sequence 344 QVAPA 348 encoding a minimal Rho tag (“mRho”, or “R”) were used to enhance the functional expression of insect ORs by promoting their exit from the endoplasmic reticulum and the transport of post-Golgi vesicles to the plasma membrane, respectively. ( b ) Schematic representation of the constructs tested. HEK293 cells were cotransfected by electroporation with 2 pcDNA3.1(-) plasmid constructs. The first, with the insertion of a human codon-optimized version of the D. melanogaster Or47a (hOr47a) tagged at the N-terminus with: a peptide composed of the mRho, mER and a V5 tag—to detect the receptor via immunochemistry if necessary—(R.E.hOr47a construct), or tagged only with the mER and V5 peptides (E.hOr47a) or the V5 tag alone (hOr47a). The second construct was constituted by a noncodon-optimized version of D. melanogaster Orco coreceptor. As controls, cells were cotransfected with the Orco coreceptor together with the empty vector backbone (EV) instead of the hOr47a construct, or with the empty vector alone. ( c ) Changes in intracellular calcium concentration over time (Δ[Ca 2+ ] i ) in HEK293 cells transfected with the constructs shown in panel (b), following stimulations with 100 µL of 100 µM of the Or47a agonist pentyl acetate (PA) at 50 s and the synthetic Orco agonist VUAA1 at 350 s. Graphs represent mean ± SD. n = 5 for each panel. Each n = 1 represents the mean of all imaged cells coming from each independent electroporated cuvette (see Methods). ( d ) Intensity of calcium responses following a pentyl acetate or a VUAA1 stimulation in cells transfected with the constructs described in panel (b). Values were extracted 50 s after a stimulation with 100 µL of 100 µM pentyl acetate, and 20 s after a stimulation with 100 µL of 100 µM VUAA1. Mean ± SD values for pentyl acetate: EV, -0.07 ± 0.63; Orco, 0.11 ± 0.64; hOr47a + Orco, 0.35 ± 0.61; E.hOr47a + Orco, 4.44 ± 0.66; R.E.hOr47a + Orco, 6.89 ± 1.41. Statistical analysis for pentyl acetate: R.E.hOr47a + Orco versus E.hOr47a + Orco: t = 3.52, P = 0.014; R.E.hOr47a + Orco versus hOr47a + Orco: t = 9.52, P < 0.001; R.E.hOr47a + Orco versus Orco: t = 9.81, P < 0.001. Mean ± SD values for VUAA1: EV, −0.68 ± 0.24; Orco, 9.52 ± 4.11; hOr47a + Orco, 15.88 ± 5.29; E.hOr47a + Orco, 45.02 ± 7.02; R.E.hOr47a + Orco, 61.32 ± 13.29. Statistical analysis for VUAA1: R.E.hOr47a + Orco versus E.hOr47a + Orco: t = 2.42, P = 0.051; R.E.hOr47a + Orco versus hOr47a + Orco: t = 7.10, P = 0.0015; R.E.hOr47a + Orco versus Orco: t = 8.32, P = 0.0015. ( e ) Percentage of responding ROIs following a pentyl acetate or a VUAA1 stimulation. Mean ± SD values for pentyl acetate: EV, 0.18 ± 0.16; Orco, 0.64 ± 0.50; hOr47a + Orco, 2.90 ± 1.05; E.hOr47a + Orco, 21.61 ± 4.16; R.E.hOr47a + Orco, 30.51 ± 6.56. Statistical analysis for pentyl acetate: R.E.hOr47a + Orco versus E.hOr47a + Orco: t = 2.56, P = 0.039; R.E.hOr47a + Orco versus hOr47a + Orco: t = 9.29, P = 0.0015; R.E.hOr47a + Orco versus Orco: t = 10.16, P = 0.0015. Mean ± SD values for VUAA1: EV, 0.06 ± 0.14; Orco, 24.12 ± 9.10; hOr47a + Orco, 30.24 ± 7.21; E.hOr47a + Orco, 61.49± 5.95; R.E.hOr47a + Orco, 71.76 ± 3.29. Statistical analysis for VUAA1: R.E.hOr47a + Orco versus E.hOr47a + Orco: t = 3.38, P = 0.015; R.E.hOr47a + Orco versus hOr47a + Orco: t = 11.71, P < 0.001; R.E.hOr47a + Orco versus Orco: W = 25, P = 0.016 (Wilcoxon rank test). Unless otherwise stated, tests are unpaired 2-tail Welch’t t -test. P values corrected for multiple comparisons using Holm’s correction. Bar plots represent mean ± SD, n = 5 for each treatment. * P < 0.05, ** P < 0.01, *** P < 0.001, ns = not significant.

Journal: Chemical Senses

Article Title: Optimization of Insect Odorant Receptor Trafficking and Functional Expression Via Transient Transfection in HEK293 Cells

doi: 10.1093/chemse/bjz062

Figure Lengend Snippet: Optimization of OR trafficking to the plasma membrane in HEK293 cells. ( a ) The human HCN1 receptor sequence 106 VNKFSL 111 encoding a minimal endoplasmic reticulum release signal (“mER”, or “E”) and the human Rhodopsin sequence 344 QVAPA 348 encoding a minimal Rho tag (“mRho”, or “R”) were used to enhance the functional expression of insect ORs by promoting their exit from the endoplasmic reticulum and the transport of post-Golgi vesicles to the plasma membrane, respectively. ( b ) Schematic representation of the constructs tested. HEK293 cells were cotransfected by electroporation with 2 pcDNA3.1(-) plasmid constructs. The first, with the insertion of a human codon-optimized version of the D. melanogaster Or47a (hOr47a) tagged at the N-terminus with: a peptide composed of the mRho, mER and a V5 tag—to detect the receptor via immunochemistry if necessary—(R.E.hOr47a construct), or tagged only with the mER and V5 peptides (E.hOr47a) or the V5 tag alone (hOr47a). The second construct was constituted by a noncodon-optimized version of D. melanogaster Orco coreceptor. As controls, cells were cotransfected with the Orco coreceptor together with the empty vector backbone (EV) instead of the hOr47a construct, or with the empty vector alone. ( c ) Changes in intracellular calcium concentration over time (Δ[Ca 2+ ] i ) in HEK293 cells transfected with the constructs shown in panel (b), following stimulations with 100 µL of 100 µM of the Or47a agonist pentyl acetate (PA) at 50 s and the synthetic Orco agonist VUAA1 at 350 s. Graphs represent mean ± SD. n = 5 for each panel. Each n = 1 represents the mean of all imaged cells coming from each independent electroporated cuvette (see Methods). ( d ) Intensity of calcium responses following a pentyl acetate or a VUAA1 stimulation in cells transfected with the constructs described in panel (b). Values were extracted 50 s after a stimulation with 100 µL of 100 µM pentyl acetate, and 20 s after a stimulation with 100 µL of 100 µM VUAA1. Mean ± SD values for pentyl acetate: EV, -0.07 ± 0.63; Orco, 0.11 ± 0.64; hOr47a + Orco, 0.35 ± 0.61; E.hOr47a + Orco, 4.44 ± 0.66; R.E.hOr47a + Orco, 6.89 ± 1.41. Statistical analysis for pentyl acetate: R.E.hOr47a + Orco versus E.hOr47a + Orco: t = 3.52, P = 0.014; R.E.hOr47a + Orco versus hOr47a + Orco: t = 9.52, P < 0.001; R.E.hOr47a + Orco versus Orco: t = 9.81, P < 0.001. Mean ± SD values for VUAA1: EV, −0.68 ± 0.24; Orco, 9.52 ± 4.11; hOr47a + Orco, 15.88 ± 5.29; E.hOr47a + Orco, 45.02 ± 7.02; R.E.hOr47a + Orco, 61.32 ± 13.29. Statistical analysis for VUAA1: R.E.hOr47a + Orco versus E.hOr47a + Orco: t = 2.42, P = 0.051; R.E.hOr47a + Orco versus hOr47a + Orco: t = 7.10, P = 0.0015; R.E.hOr47a + Orco versus Orco: t = 8.32, P = 0.0015. ( e ) Percentage of responding ROIs following a pentyl acetate or a VUAA1 stimulation. Mean ± SD values for pentyl acetate: EV, 0.18 ± 0.16; Orco, 0.64 ± 0.50; hOr47a + Orco, 2.90 ± 1.05; E.hOr47a + Orco, 21.61 ± 4.16; R.E.hOr47a + Orco, 30.51 ± 6.56. Statistical analysis for pentyl acetate: R.E.hOr47a + Orco versus E.hOr47a + Orco: t = 2.56, P = 0.039; R.E.hOr47a + Orco versus hOr47a + Orco: t = 9.29, P = 0.0015; R.E.hOr47a + Orco versus Orco: t = 10.16, P = 0.0015. Mean ± SD values for VUAA1: EV, 0.06 ± 0.14; Orco, 24.12 ± 9.10; hOr47a + Orco, 30.24 ± 7.21; E.hOr47a + Orco, 61.49± 5.95; R.E.hOr47a + Orco, 71.76 ± 3.29. Statistical analysis for VUAA1: R.E.hOr47a + Orco versus E.hOr47a + Orco: t = 3.38, P = 0.015; R.E.hOr47a + Orco versus hOr47a + Orco: t = 11.71, P < 0.001; R.E.hOr47a + Orco versus Orco: W = 25, P = 0.016 (Wilcoxon rank test). Unless otherwise stated, tests are unpaired 2-tail Welch’t t -test. P values corrected for multiple comparisons using Holm’s correction. Bar plots represent mean ± SD, n = 5 for each treatment. * P < 0.05, ** P < 0.01, *** P < 0.001, ns = not significant.

Article Snippet: Primer sequences are listed in the Full sequences for the reported constructs and plasmid availability information are accessible at Addgene ( https://www.addgene.org ) with the following reference numbers: pcDNA3.1(-)-mRho.V5.mER.hOr47a: #126472; pcDNA3.1(-)-V5.mER.hOr47a: #126473; pcDNA3.1(-)-V5.hOr47a: #126474; pCMV-BI: #126475; pDmelOR: #126476; pDmelOR-mRho.V5.mER.hOr47a: #126478; pDmelOR-mRho.V5.mER.hOr56a: #126479.

Techniques: Sequencing, Functional Assay, Expressing, Construct, Electroporation, Plasmid Preparation, Concentration Assay, Transfection

Analysis of insect OR agonist sensitivity and specificity by means of an automated imaging platform. ( a ) Normalization of the odor response respect to the VUAA1 internal control. After calculating the ratio (R) between the emission light at 340 nm and 380 nm, base levels were subtracted from peak agonist responses to obtain the odor, e.g., pentyl acetate (PA), and the VUAA1 net responses (∆x and ∆y, respectively). The ratio ϱ ( rho ) between the odor and VUAA1 net responses expressed in percentage (ϱ = [∆x/∆y]*100) can be used to account for the cell-specific OR expression level due to the transient transfection protocol. ( b,c ) Example showing how normalization of the odor response to the VUAA1 internal control can reduce response variability. (b) Time series of R (340/380 nm) ratios for 2 regions of interests (ROI1 and ROI2) showing different response intensities to the same odor and VUAA1 stimulation. (c) Time series of normalized ϱ values for the odor responses of the same ROI1 and ROI2 as shown in panel (b). ϱ values reveal that both ROI1 and ROI2 show a very similar maximal response to the PA stimulation. ( d,e ) Dose–response curve for HEK293 cells transfected with pDmelOR-R.E.hOr47a and stimulated with pentyl acetate (d), or with pDmelOR-R.E.hOr56a and stimulated with geosmin (e). Data were fitted to a 3-parameter logistic function using the drc package in R (see ). Values of the data fit (mean ± st. error) for pDmelOR-R.E.hOr47a: slope, −2.89 ± 0.42; upper limit, 30.80 ± 1.28; EC 50 (log), −4.61 ± 0.06. EC 50 values expressed in Molar (estimate, 2.5% and 97.5% confidence intervals): 2.45·10 –5 (1.83 × 10 –5 ; 3.29 × 10 –5 ). Values of the data fit for pDmelOR-R.E.hOr56a: slope, −2.46 ± 0.58; upper limit, 11.93 ± 0.92; EC 50 (log), −6.14 ± 0.13. EC 50 values expressed in Molar (estimate, 2.5% and 97.5% confidence intervals): 7.19·10 –7 (3.97 × 10 –7 ; 1.30 × 10 –6 ). Plot shows estimate ± SE. F or 5 ≤ n ≤ 6 (b) and n = 7 (c) for each odor concentration. ( f ) Odor response profile for Or47a using the pDmelOR-R.E.hOr47a construct. Odors are disposed according to their expected potency as agonists according to the DoOR database (see ). Kruskall-Wallis rank sum test: χ 2 = 50.148, df = 9, P < 0.001. Post-hoc Dunnett’s test for comparing each treatment versus DMSO. 3-octanol versus DMSO, P = 0.039; 2-heptanone versus DMSO, P < 0.001; isobutyl acetate versus DMSO, P = 0.013; hexyl acetate versus DMSO, P = 0.002; 3-methylthio-1-propanol (FG) versus DMSO, P = 1; propyl acetate (AG) versus DMSO, P = 0.036; methyl hexanoate versus DMSO, P < 0.001; butyl hexanoate versus DMSO, P < 0.001; pentyl acetate versus DMSO, P < 0.001. 4 ≤ n ≤ 10. The red box highlights 2 odors whose response intensities do not follow the expected trend, i.e., 3-methilthio-1-propanol and pentyl acetate. ( g ) The effect of propyl acetate is consistent across commercial stocks with different purity. The response to pentyl acetate was significant compared to the DMSO control when working solutions were prepared from a 99% purity stock odor (Sigma-Aldrich, Cat. Nr. 133108), and a ≥99% analytical standard grade (AG) stock odor (Fluka, Cat. Nr. 40858). Kruskall–Wallis rank sum test: χ 2 = 10.088, df = 2, P = 0.0064. Post-hoc Dunnett’s test for comparing each treatment versus DMSO. 99% versus DMSO, P = 0.0147; ≥99% AG versus DMSO, P = 0.0147. 4 ≤ n ≤ 9. ( h ) The effect of 3-methilthio-1-propanol is not consistent across commercial stocks with different purity. Responses were significant compared to the DMSO control when working solutions were prepared from a 98% purity stock odor (Sigma-Aldrich, Cat. Nr. 318396), but not from a ≥98% food/pharmaceutical (FG) grade stock odor (Sigma-Aldrich, Cat. Nr. W341509). Kruskall–Wallis rank sum test: χ 2 = 8.681, df = 2, P = 0.013. Post-hoc Dunnett’s test for comparing each treatment versus DMSO. 98% versus DMSO, P = 0.904; ≥98% (FG) versus DMSO: P < 0.001. 4 ≤ n ≤ 9. ( i ) Responses of HEK293 cells transfected with the pCMV-BI empty vector to odor stimuli (300 µM for all odors, except 30 µM for geosmin) and DMSO. Kruskall–Wallis rank sum test: χ 2 = 27.115, df = 12, P = 0.0074. Post-hoc Dunnett’s test for comparing each treatment versus DMSO. 3-octanol versus DMSO, P = 0.00064; 2-heptanone versus DMSO, P = 0.734; isobutyl acetate versus DMSO, P = 0.996; hexyl acetate versus DMSO, P = 0.949; 3-methylthio-1-propanol (98%) versus DMSO, P = 0.762; 3-methylthio-1-propanol (FG) versus DMSO, P = 0.572; propyl acetate (99%) versus DMSO, P = 0.922; propyl acetate (AG) versus DMSO, P > 0.999; methyl hexanoate versus DMSO, P > 0.999; butyl acetate versus DMSO, P > 0.999; pentyl acetate versus DMSO, P = 0.961; geosmin versus DMSO, P = 0.749. For geosmin, one data point (black circle in the bar plot) was considered as an outlier and was omitted from analysis. 2 ≤ n ≤ 11. *** P < 0.001, ** P < 0.01, * P < 0.05.

Journal: Chemical Senses

Article Title: Optimization of Insect Odorant Receptor Trafficking and Functional Expression Via Transient Transfection in HEK293 Cells

doi: 10.1093/chemse/bjz062

Figure Lengend Snippet: Analysis of insect OR agonist sensitivity and specificity by means of an automated imaging platform. ( a ) Normalization of the odor response respect to the VUAA1 internal control. After calculating the ratio (R) between the emission light at 340 nm and 380 nm, base levels were subtracted from peak agonist responses to obtain the odor, e.g., pentyl acetate (PA), and the VUAA1 net responses (∆x and ∆y, respectively). The ratio ϱ ( rho ) between the odor and VUAA1 net responses expressed in percentage (ϱ = [∆x/∆y]*100) can be used to account for the cell-specific OR expression level due to the transient transfection protocol. ( b,c ) Example showing how normalization of the odor response to the VUAA1 internal control can reduce response variability. (b) Time series of R (340/380 nm) ratios for 2 regions of interests (ROI1 and ROI2) showing different response intensities to the same odor and VUAA1 stimulation. (c) Time series of normalized ϱ values for the odor responses of the same ROI1 and ROI2 as shown in panel (b). ϱ values reveal that both ROI1 and ROI2 show a very similar maximal response to the PA stimulation. ( d,e ) Dose–response curve for HEK293 cells transfected with pDmelOR-R.E.hOr47a and stimulated with pentyl acetate (d), or with pDmelOR-R.E.hOr56a and stimulated with geosmin (e). Data were fitted to a 3-parameter logistic function using the drc package in R (see ). Values of the data fit (mean ± st. error) for pDmelOR-R.E.hOr47a: slope, −2.89 ± 0.42; upper limit, 30.80 ± 1.28; EC 50 (log), −4.61 ± 0.06. EC 50 values expressed in Molar (estimate, 2.5% and 97.5% confidence intervals): 2.45·10 –5 (1.83 × 10 –5 ; 3.29 × 10 –5 ). Values of the data fit for pDmelOR-R.E.hOr56a: slope, −2.46 ± 0.58; upper limit, 11.93 ± 0.92; EC 50 (log), −6.14 ± 0.13. EC 50 values expressed in Molar (estimate, 2.5% and 97.5% confidence intervals): 7.19·10 –7 (3.97 × 10 –7 ; 1.30 × 10 –6 ). Plot shows estimate ± SE. F or 5 ≤ n ≤ 6 (b) and n = 7 (c) for each odor concentration. ( f ) Odor response profile for Or47a using the pDmelOR-R.E.hOr47a construct. Odors are disposed according to their expected potency as agonists according to the DoOR database (see ). Kruskall-Wallis rank sum test: χ 2 = 50.148, df = 9, P < 0.001. Post-hoc Dunnett’s test for comparing each treatment versus DMSO. 3-octanol versus DMSO, P = 0.039; 2-heptanone versus DMSO, P < 0.001; isobutyl acetate versus DMSO, P = 0.013; hexyl acetate versus DMSO, P = 0.002; 3-methylthio-1-propanol (FG) versus DMSO, P = 1; propyl acetate (AG) versus DMSO, P = 0.036; methyl hexanoate versus DMSO, P < 0.001; butyl hexanoate versus DMSO, P < 0.001; pentyl acetate versus DMSO, P < 0.001. 4 ≤ n ≤ 10. The red box highlights 2 odors whose response intensities do not follow the expected trend, i.e., 3-methilthio-1-propanol and pentyl acetate. ( g ) The effect of propyl acetate is consistent across commercial stocks with different purity. The response to pentyl acetate was significant compared to the DMSO control when working solutions were prepared from a 99% purity stock odor (Sigma-Aldrich, Cat. Nr. 133108), and a ≥99% analytical standard grade (AG) stock odor (Fluka, Cat. Nr. 40858). Kruskall–Wallis rank sum test: χ 2 = 10.088, df = 2, P = 0.0064. Post-hoc Dunnett’s test for comparing each treatment versus DMSO. 99% versus DMSO, P = 0.0147; ≥99% AG versus DMSO, P = 0.0147. 4 ≤ n ≤ 9. ( h ) The effect of 3-methilthio-1-propanol is not consistent across commercial stocks with different purity. Responses were significant compared to the DMSO control when working solutions were prepared from a 98% purity stock odor (Sigma-Aldrich, Cat. Nr. 318396), but not from a ≥98% food/pharmaceutical (FG) grade stock odor (Sigma-Aldrich, Cat. Nr. W341509). Kruskall–Wallis rank sum test: χ 2 = 8.681, df = 2, P = 0.013. Post-hoc Dunnett’s test for comparing each treatment versus DMSO. 98% versus DMSO, P = 0.904; ≥98% (FG) versus DMSO: P < 0.001. 4 ≤ n ≤ 9. ( i ) Responses of HEK293 cells transfected with the pCMV-BI empty vector to odor stimuli (300 µM for all odors, except 30 µM for geosmin) and DMSO. Kruskall–Wallis rank sum test: χ 2 = 27.115, df = 12, P = 0.0074. Post-hoc Dunnett’s test for comparing each treatment versus DMSO. 3-octanol versus DMSO, P = 0.00064; 2-heptanone versus DMSO, P = 0.734; isobutyl acetate versus DMSO, P = 0.996; hexyl acetate versus DMSO, P = 0.949; 3-methylthio-1-propanol (98%) versus DMSO, P = 0.762; 3-methylthio-1-propanol (FG) versus DMSO, P = 0.572; propyl acetate (99%) versus DMSO, P = 0.922; propyl acetate (AG) versus DMSO, P > 0.999; methyl hexanoate versus DMSO, P > 0.999; butyl acetate versus DMSO, P > 0.999; pentyl acetate versus DMSO, P = 0.961; geosmin versus DMSO, P = 0.749. For geosmin, one data point (black circle in the bar plot) was considered as an outlier and was omitted from analysis. 2 ≤ n ≤ 11. *** P < 0.001, ** P < 0.01, * P < 0.05.

Article Snippet: Primer sequences are listed in the Full sequences for the reported constructs and plasmid availability information are accessible at Addgene ( https://www.addgene.org ) with the following reference numbers: pcDNA3.1(-)-mRho.V5.mER.hOr47a: #126472; pcDNA3.1(-)-V5.mER.hOr47a: #126473; pcDNA3.1(-)-V5.hOr47a: #126474; pCMV-BI: #126475; pDmelOR: #126476; pDmelOR-mRho.V5.mER.hOr47a: #126478; pDmelOR-mRho.V5.mER.hOr56a: #126479.

Techniques: Imaging, Expressing, Transfection, Concentration Assay, Construct, Plasmid Preparation

(a) The human HCN1 receptor sequence 106 VNKFSL 111 encoding a minimal endoplasmic reticulum release signal (

Journal: bioRxiv

Article Title: Optimization of insect odorant receptor trafficking and functional expression via transient transfection in HEK293 cells

doi: 10.1101/669127

Figure Lengend Snippet: (a) The human HCN1 receptor sequence 106 VNKFSL 111 encoding a minimal endoplasmic reticulum release signal ("mER", or "E") and the human Rhodopsin sequence 344 QVAPA 348 encoding a minimal Rho tag ("mRho", or "R") were used to enhance the functional expression of insect ORs by promoting their exit from the endoplasmic reticulum and the transport of post-Golgi vesicles to the plasma membrane, respectively. (b) Schematic representation of the constructs tested. HEK293 cells were co-transfected by electroporation with two pcDNA3.1(-) plasmid constructs. The first, with the insertion of a human codon-optimized version of the D. melanogaster Or47a (hOr47a) tagged at the N-terminus with: a peptide composed of the mRho, mER and a V5 tag – to detect the receptor via immunochemistry if necessary – (R.E.hOr47a construct), or tagged only with the mER and V5 peptides (E.hOr47a) or the V5 tag alone (hOr47a). The second construct was constituted by a non codon-optimized version of D. melanogaster Orco co-receptor. As controls, cells were co-transfected with the Orco co-receptor together with the empty vector backbone (EV) instead of the hOr47a construct, or with the empty vector alone. (c) Changes in intracellular calcium concentration over time (Δ[Ca 2+ ] i ) in HEK293 cells transfected with the constructs shown in panel (b), following stimulations with 100 µl of 100 µM of the Or47a agonist pentyl acetate (PA) at 50 s and the synthetic Orco agonist VUAA1 at 350 s. Graphs represent mean ± SD. n = 5 for each panel. Each n = 1 represents the mean of all imaged cells coming from each independent electroporated cuvette (see Methods). (d) Intensity of calcium responses following a pentyl acetate or a VUAA1 stimulation in cells transfected with the constructs described in panel (b). Values were extracted 50 s after a stimulation with 100 µl of 100 µM pentyl acetate, and 20 s after a stimulation with 100 µl of 100 µM VUAA1. Mean ± SD values for pentyl acetate: EV, −0.07 ± 0.63; Orco, 0.11 ± 0.64; hOr47a + Orco, 0.35 ± 0.61; E.hOr47a + Orco, 4.44 ± 0.66; R.E.hOr47a + Orco, 6.89 ± 1.41. Statistical analysis for pentyl acetate: R.E.hOr47a + Orco versus (vs.) E.hOr47a + Orco: t = 3.52, p = 0.014; R.E.hOr47a + Orco vs. hOr47a + Orco: t = 9.52, p < 0.001; R.E.hOr47a + Orco vs. Orco: t = 9.81, p < 0.001. Mean ± SD values for VUAA1: EV, −0.68 ± 0.24; Orco, 9.52 ± 4.11; hOr47a + Orco, 15.88 ± 5.29; E.hOr47a + Orco, 45.02 ± 7.02; R.E.hOr47a + Orco, 61.32 ± 13.29. Statistical analysis for VUAA1: R.E.hOr47a + Orco versus (vs.) E.hOr47a + Orco: t = 2.42, p = 0.051; R.E.hOr47a + Orco vs. hOr47a + Orco: t = 7.10, p = 0.0015; R.E.hOr47a + Orco vs. Orco: t = 8.32, p = 0.0015. (e) Percentage of responding ROIs following a pentyl acetate or a VUAA1 stimulation. Mean ± SD values for pentyl acetate: EV, 0.18 ± 0.16; Orco, 0.64 ± 0.50; hOr47a + Orco, 2.90 ± 1.05; E.hOr47a + Orco, 21.61 ± 4.16; R.E.hOr47a + Orco, 30.51 ± 6.56. Statistical analysis for pentyl acetate: R.E.hOr47a + Orco versus (vs.) E.hOr47a + Orco: t = 2.56, p = 0.039; R.E.hOr47a + Orco vs. hOr47a + Orco: t = 9.29, p = 0.0015; R.E.hOr47a + Orco vs. Orco: t = 10.16, p = 0.0015. Mean ± SD values for VUAA1: EV, 0.06 ± 0.14; Orco, 24.12 ± 9.10; hOr47a + Orco, 30.24 ± 7.21; E.hOr47a + Orco, 61.49± 5.95; R.E.hOr47a + Orco, 71.76 ± 3.29. Statistical analysis for VUAA1: R.E.hOr47a + Orco versus (vs.) E.hOr47a + Orco: t = 3.38, p = 0.015; R.E.hOr47a + Orco vs. hOr47a + Orco: t = 11.71, p < 0.001; R.E.hOr47a + Orco vs. Orco: W = 25, p = 0.016 (Wilcoxon rank test). Unless otherwise stated, tests are unpaired two-tails Welch’t t-test. P values corrected for multiple comparisons using Holm’s correction. Bar plots represent mean ± SD, n = 5 for each treatment. * p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant.

Article Snippet: Full sequences for the reported constructs and plasmid availability information are accessible at Addgene ( https://www.addgene.org ) with the following reference numbers: pcDNA3.1(-)-mRho.V5.mER.hOr47a: #126472; pcDNA3.1(-)-V5.mER.hOr47a: #126473; pcDNA3.1(-)-V5.hOr47a: #126474; pCMV-BI: #126475; pDmelOR: #126476; pDmelOR-mRho.V5.mER.hOr47a: #126478; pDmelOR-mRho.V5.mER.hOr56a: #126479.

Techniques: Sequencing, Functional Assay, Expressing, Construct, Transfection, Electroporation, Plasmid Preparation, Concentration Assay

(a-b) Examples of calcium imaging experiments with HEK293 cells co-transfected with the R.E.hOr47a + Orco constructs in two different pcDNA3.1(-) vectors (a) and with the pDmelOR-R.E.hOr47a housing both the hOr47a and a codon-optimized version of Orco (hOrco) bearing the β-globin/IgG chimeric intron (c.i.) (b). Panels represent – from left to right – a schematic representation of the constructs tested; transmission light image of the tested HEK293 cells; base level [Ca 2+ ] i of transfected HEK293 cells (0 s); [Ca 2+ ] i 25 s after application of 100 µl of 100 µM pentyl acetate (75 s) and 25 s after application of 100 µl of 100 µM VUAA1 (375 s). Scale bar = 50 µm. (c) Changes in intracellular calcium concentration over time (Δ[Ca 2+ ] i ) in HEK293 cells transfected with the construct shown in panels (a-b), following stimulations with 100 µl of 100 µM of the Or47a agonist pentyl acetate (PA) at 50 s and the synthetic Orco agonist VUAA1 at 350 s. Graphs represent mean ± SD. n = 5 for R.E.hOr47a + Orco and n = 3 for pDmelOR-R.E.hOr47a. Each n = 1 represents the mean of all imaged cells coming from independently electroporated cuvettes (see Methods). (d) Intensity of calcium responses following a pentyl acetate or a VUAA1 stimulation in cells transfected with the constructs described in panels (a-b). Δ[Ca 2+ ] i values were extracted 50 s after a stimulation with 100 µl of 100 µM pentyl acetate, and 20 s after a stimulation with 100 µl of 100 µM VUAA1. Mean ± SD values for pentyl acetate: R.E.hOr47a + Orco, 6.89 ± 1.41; pDmelOR-R.E.hOr47a, 38.43 ± 6.04. Statistical analysis for pentyl acetate: pDmelOR-R.E.hOr47a versus R.E.hOr47a + Orco, t = 8.90, p = 0.010, Two tailed Welch’s t test. Mean ± SD values for VUAA1: R.E.hOr47a + Orco, 61.32 ± 13.29; pDmelOR-R.E.hOr47a + Orco, 149.24 ± 20.12. Statistical analysis for VUAA1: pDmelOR-R.E.hOr47a versus R.E.hOr47a + Orco, W = 15, p = 0.036, Wilcoxon rank sum test. Graphs represent mean ± SD. n = 5 for R.E.hOr47a + Orco and n = 3 for pDmelOR-R.E.hOr47a. (e) Percentage of responding ROIs following a pentyl acetate or a VUAA1 stimulation. Mean ± SD values for pentyl acetate: R.E.hOr47a + Orco, 30.51 ± 6.56; pDmelOR-R.E.hOr47a, 76.01± 10.64. Statistical analysis for pentyl acetate: pDmelOR-R.E.hOr47a versus R.E.hOr47a + Orco: t = 6.68, p = 0.0073. Mean ± SD values for VUAA1: R.E.hOr47a + Orco, 71.76 ± 3.29; pDmelOR-R.E.hOr47a, 92.47± 4.03. Statistical analysis for VUAA1: pDmelOR-R.E.hOr47a versus R.E.hOr47a + Orco: t = 7.52, p = 0.0024. Two-tailed Welch’s t tests. Graphs represent mean ± SD. n = 5 for R.E.hOr47a + Orco and n = 3 for pDmelOR-R.E.hOr47a.

Journal: bioRxiv

Article Title: Optimization of insect odorant receptor trafficking and functional expression via transient transfection in HEK293 cells

doi: 10.1101/669127

Figure Lengend Snippet: (a-b) Examples of calcium imaging experiments with HEK293 cells co-transfected with the R.E.hOr47a + Orco constructs in two different pcDNA3.1(-) vectors (a) and with the pDmelOR-R.E.hOr47a housing both the hOr47a and a codon-optimized version of Orco (hOrco) bearing the β-globin/IgG chimeric intron (c.i.) (b). Panels represent – from left to right – a schematic representation of the constructs tested; transmission light image of the tested HEK293 cells; base level [Ca 2+ ] i of transfected HEK293 cells (0 s); [Ca 2+ ] i 25 s after application of 100 µl of 100 µM pentyl acetate (75 s) and 25 s after application of 100 µl of 100 µM VUAA1 (375 s). Scale bar = 50 µm. (c) Changes in intracellular calcium concentration over time (Δ[Ca 2+ ] i ) in HEK293 cells transfected with the construct shown in panels (a-b), following stimulations with 100 µl of 100 µM of the Or47a agonist pentyl acetate (PA) at 50 s and the synthetic Orco agonist VUAA1 at 350 s. Graphs represent mean ± SD. n = 5 for R.E.hOr47a + Orco and n = 3 for pDmelOR-R.E.hOr47a. Each n = 1 represents the mean of all imaged cells coming from independently electroporated cuvettes (see Methods). (d) Intensity of calcium responses following a pentyl acetate or a VUAA1 stimulation in cells transfected with the constructs described in panels (a-b). Δ[Ca 2+ ] i values were extracted 50 s after a stimulation with 100 µl of 100 µM pentyl acetate, and 20 s after a stimulation with 100 µl of 100 µM VUAA1. Mean ± SD values for pentyl acetate: R.E.hOr47a + Orco, 6.89 ± 1.41; pDmelOR-R.E.hOr47a, 38.43 ± 6.04. Statistical analysis for pentyl acetate: pDmelOR-R.E.hOr47a versus R.E.hOr47a + Orco, t = 8.90, p = 0.010, Two tailed Welch’s t test. Mean ± SD values for VUAA1: R.E.hOr47a + Orco, 61.32 ± 13.29; pDmelOR-R.E.hOr47a + Orco, 149.24 ± 20.12. Statistical analysis for VUAA1: pDmelOR-R.E.hOr47a versus R.E.hOr47a + Orco, W = 15, p = 0.036, Wilcoxon rank sum test. Graphs represent mean ± SD. n = 5 for R.E.hOr47a + Orco and n = 3 for pDmelOR-R.E.hOr47a. (e) Percentage of responding ROIs following a pentyl acetate or a VUAA1 stimulation. Mean ± SD values for pentyl acetate: R.E.hOr47a + Orco, 30.51 ± 6.56; pDmelOR-R.E.hOr47a, 76.01± 10.64. Statistical analysis for pentyl acetate: pDmelOR-R.E.hOr47a versus R.E.hOr47a + Orco: t = 6.68, p = 0.0073. Mean ± SD values for VUAA1: R.E.hOr47a + Orco, 71.76 ± 3.29; pDmelOR-R.E.hOr47a, 92.47± 4.03. Statistical analysis for VUAA1: pDmelOR-R.E.hOr47a versus R.E.hOr47a + Orco: t = 7.52, p = 0.0024. Two-tailed Welch’s t tests. Graphs represent mean ± SD. n = 5 for R.E.hOr47a + Orco and n = 3 for pDmelOR-R.E.hOr47a.

Article Snippet: Full sequences for the reported constructs and plasmid availability information are accessible at Addgene ( https://www.addgene.org ) with the following reference numbers: pcDNA3.1(-)-mRho.V5.mER.hOr47a: #126472; pcDNA3.1(-)-V5.mER.hOr47a: #126473; pcDNA3.1(-)-V5.hOr47a: #126474; pCMV-BI: #126475; pDmelOR: #126476; pDmelOR-mRho.V5.mER.hOr47a: #126478; pDmelOR-mRho.V5.mER.hOr56a: #126479.

Techniques: Imaging, Transfection, Construct, Transmission Assay, Concentration Assay, Two Tailed Test

(a) Normalization of the odor response respect to the VUAA1 internal control. After calculating the ratio (R) between the emission light at 340 nm and 380 nm, base levels were subtracted from peak agonist responses to obtain the odor, e.g. pentyl acetate (PA), and the VUAA1 net responses (∆x and ∆y, respectively). The ratio ϱ ( rho ) between the odor and VUAA1 net responses expressed in percentage (ϱ = [∆x/∆y]*100) can be used to account for the cell-specific OR expression level due to the transient transfection protocol. (b-c) Example showing how normalization of the odor response to the VUAA1 internal control can reduce response variability. (b) Time series of R (340/380 nm) ratios for two regions of interests (ROI1 and ROI2) showing different response intensities to the same odor and VUAA1 stimulation. (c) Time series of normalized ϱ values for the odor responses of the same ROI1 and ROI2 as shown in panel (b). ϱ values reveal that both ROI1 and ROI2 show a very similar maximal response to the PA stimulation. (d-e) Dose-response curve for HEK293 cells transfected with pDmelOR-R.E.hOr47a and stimulated with pentyl acetate (d), or with pDmelOR-R.E.hOr56a and stimulated with geosmin (e). Data were fitted to a 3-parameter logistic function using the drc package in R (see Supplementary Code). Values of the data fit (mean ± st. error) for pDmelOR-R.E.hOr47a: slope, −2.89 ± 0.42; upper limit, 30.80 ± 1.28; EC 50 (log), −4.61 ± 0.06. EC 50 values expressed in Molar (estimate, 2.5% and 97.5% confidence intervals): 2.45⋅10 −5 (1.83⋅10 −5 ; 3.29⋅10 −5 ). Values of the data fit for pDmelOR-R.E.hOr56a: slope, −2.46 ± 0.58; upper limit, 11.93 ± 0.92; EC 50 (log), −6.14 ± 0.13. EC 50 values expressed in Molar (estimate, 2.5% and 97.5% confidence intervals): 7.19⋅10 −7 (3.97⋅10 −7 ; 1.30⋅10 −6 ). Plot shows estimate ± S.E. For 5 ≤ n ≤ 6 (b) and n = 7 (c) for each odor concentration. (f) Odor response profile for Or47a using the pDmelOR-R.E.hOr47a construct. Odors are disposed according to their expected potency as agonists according to the DoOR database (see ). Kruskall-Wallis rank sum test: χ 2 = 50.148, df = 9, p < 0.001. Post-hoc Dunnett’s test for comparing each treatment versus (vs.) DMSO. 3-octanol vs. DMSO, p = 0.039; 2-heptanone vs. DMSO, p < 0.001; isobutyl acetate vs. DMSO, p = 0.013; hexyl acetate vs. DMSO, p = 0.002; 3-methylthio-1-propanol (FG) vs. DMSO, p = 1; propyl acetate (AG) vs. DMSO, p = 0.036; methyl hexanoate vs. DMSO, p < 0.001; butyl hexanoate vs. DMSO, p < 0.001; pentyl acetate vs. DMSO, p < 0.001. 4 ≤ n ≤ 10. The red box highlights two odors whose response intensities do not follow the expected trend, i.e. 3-methilthio-1-propanol and pentyl acetate. (g) The effect of propyl acetate is consistent across commercial stocks with different purity. The response to pentyl acetate was significant compared to the DMSO control when working solutions were prepared from a 99% purity stock odor (Sigma-Aldrich, Cat. Nr. 133108), and a ≥99% analytical standard grade (AG) stock odor (Fluka, Cat. Nr. 40858). Kruskall-Wallis rank sum test: χ 2 = 10.088, df = 2, p = 0.0064. Post-hoc Dunnett’s test for comparing each treatment versus (vs.) DMSO. 99% vs. DMSO, p = 0.0147; ≥99% AG vs. DMSO, p = 0.0147. 4 ≤ n ≤ 9. (h) The effect of 3-methilthio-1-propanol is not consistent across commercial stocks with different purity. Responses were significant compared to the DMSO control when working solutions were prepared from a 98% purity stock odor (Sigma-Aldrich, Cat. Nr. 318396), but not from a ≥98% food/pharmaceutical (FG) grade stock odor (Sigma-Aldrich, Cat. Nr. W341509). Kruskall-Wallis rank sum test: χ 2 = 8.681, df = 2, p = 0.013. Post-hoc Dunnett’s test for comparing each treatment versus (vs.) DMSO. 98% vs. DMSO, p = 0.904; ≥98% (FG) vs. DMSO: p < 0.001. 4 ≤ n ≤ 9. (i) Responses of HEK293 cells transfected with the pCMV-BI empty vector to odor stimuli (300 µM for all odors, except 30 µM for geosmin) and DMSO. Kruskall-Wallis rank sum test: χ 2 = 27.115, df = 12, p = 0.0074. Post-hoc Dunnett’s test for comparing each treatment versus (vs.) DMSO. 3-octanol vs. DMSO, p = 0.00064; 2-heptanone vs. DMSO, p = 0.734; isobutyl acetate versus (vs.) DMSO, p = 0.996; hexyl acetate vs. DMSO, p = 0.949; 3-methylthio-1-propanol (98%) vs. DMSO, p = 0.762; 3-methylthio-1-propanol (FG) vs. DMSO, p = 0.572; propyl acetate (99%) vs. DMSO, p = 0.922; propyl acetate (AG) vs. DMSO, p > 0.999; methyl hexanoate vs. DMSO, p > 0.999; butyl acetate vs. DMSO, p > 0.999; pentyl acetate vs. DMSO, p = 0.961; geosmin vs. DMSO, p = 0.749. For geosmin, one data point (black circle in the bar plot) was considered as an outlier and was omitted from analysis. 2 ≤ n ≤ 11. *** p < 0.001, ** p < 0.01, * p < 0.05.

Journal: bioRxiv

Article Title: Optimization of insect odorant receptor trafficking and functional expression via transient transfection in HEK293 cells

doi: 10.1101/669127

Figure Lengend Snippet: (a) Normalization of the odor response respect to the VUAA1 internal control. After calculating the ratio (R) between the emission light at 340 nm and 380 nm, base levels were subtracted from peak agonist responses to obtain the odor, e.g. pentyl acetate (PA), and the VUAA1 net responses (∆x and ∆y, respectively). The ratio ϱ ( rho ) between the odor and VUAA1 net responses expressed in percentage (ϱ = [∆x/∆y]*100) can be used to account for the cell-specific OR expression level due to the transient transfection protocol. (b-c) Example showing how normalization of the odor response to the VUAA1 internal control can reduce response variability. (b) Time series of R (340/380 nm) ratios for two regions of interests (ROI1 and ROI2) showing different response intensities to the same odor and VUAA1 stimulation. (c) Time series of normalized ϱ values for the odor responses of the same ROI1 and ROI2 as shown in panel (b). ϱ values reveal that both ROI1 and ROI2 show a very similar maximal response to the PA stimulation. (d-e) Dose-response curve for HEK293 cells transfected with pDmelOR-R.E.hOr47a and stimulated with pentyl acetate (d), or with pDmelOR-R.E.hOr56a and stimulated with geosmin (e). Data were fitted to a 3-parameter logistic function using the drc package in R (see Supplementary Code). Values of the data fit (mean ± st. error) for pDmelOR-R.E.hOr47a: slope, −2.89 ± 0.42; upper limit, 30.80 ± 1.28; EC 50 (log), −4.61 ± 0.06. EC 50 values expressed in Molar (estimate, 2.5% and 97.5% confidence intervals): 2.45⋅10 −5 (1.83⋅10 −5 ; 3.29⋅10 −5 ). Values of the data fit for pDmelOR-R.E.hOr56a: slope, −2.46 ± 0.58; upper limit, 11.93 ± 0.92; EC 50 (log), −6.14 ± 0.13. EC 50 values expressed in Molar (estimate, 2.5% and 97.5% confidence intervals): 7.19⋅10 −7 (3.97⋅10 −7 ; 1.30⋅10 −6 ). Plot shows estimate ± S.E. For 5 ≤ n ≤ 6 (b) and n = 7 (c) for each odor concentration. (f) Odor response profile for Or47a using the pDmelOR-R.E.hOr47a construct. Odors are disposed according to their expected potency as agonists according to the DoOR database (see ). Kruskall-Wallis rank sum test: χ 2 = 50.148, df = 9, p < 0.001. Post-hoc Dunnett’s test for comparing each treatment versus (vs.) DMSO. 3-octanol vs. DMSO, p = 0.039; 2-heptanone vs. DMSO, p < 0.001; isobutyl acetate vs. DMSO, p = 0.013; hexyl acetate vs. DMSO, p = 0.002; 3-methylthio-1-propanol (FG) vs. DMSO, p = 1; propyl acetate (AG) vs. DMSO, p = 0.036; methyl hexanoate vs. DMSO, p < 0.001; butyl hexanoate vs. DMSO, p < 0.001; pentyl acetate vs. DMSO, p < 0.001. 4 ≤ n ≤ 10. The red box highlights two odors whose response intensities do not follow the expected trend, i.e. 3-methilthio-1-propanol and pentyl acetate. (g) The effect of propyl acetate is consistent across commercial stocks with different purity. The response to pentyl acetate was significant compared to the DMSO control when working solutions were prepared from a 99% purity stock odor (Sigma-Aldrich, Cat. Nr. 133108), and a ≥99% analytical standard grade (AG) stock odor (Fluka, Cat. Nr. 40858). Kruskall-Wallis rank sum test: χ 2 = 10.088, df = 2, p = 0.0064. Post-hoc Dunnett’s test for comparing each treatment versus (vs.) DMSO. 99% vs. DMSO, p = 0.0147; ≥99% AG vs. DMSO, p = 0.0147. 4 ≤ n ≤ 9. (h) The effect of 3-methilthio-1-propanol is not consistent across commercial stocks with different purity. Responses were significant compared to the DMSO control when working solutions were prepared from a 98% purity stock odor (Sigma-Aldrich, Cat. Nr. 318396), but not from a ≥98% food/pharmaceutical (FG) grade stock odor (Sigma-Aldrich, Cat. Nr. W341509). Kruskall-Wallis rank sum test: χ 2 = 8.681, df = 2, p = 0.013. Post-hoc Dunnett’s test for comparing each treatment versus (vs.) DMSO. 98% vs. DMSO, p = 0.904; ≥98% (FG) vs. DMSO: p < 0.001. 4 ≤ n ≤ 9. (i) Responses of HEK293 cells transfected with the pCMV-BI empty vector to odor stimuli (300 µM for all odors, except 30 µM for geosmin) and DMSO. Kruskall-Wallis rank sum test: χ 2 = 27.115, df = 12, p = 0.0074. Post-hoc Dunnett’s test for comparing each treatment versus (vs.) DMSO. 3-octanol vs. DMSO, p = 0.00064; 2-heptanone vs. DMSO, p = 0.734; isobutyl acetate versus (vs.) DMSO, p = 0.996; hexyl acetate vs. DMSO, p = 0.949; 3-methylthio-1-propanol (98%) vs. DMSO, p = 0.762; 3-methylthio-1-propanol (FG) vs. DMSO, p = 0.572; propyl acetate (99%) vs. DMSO, p = 0.922; propyl acetate (AG) vs. DMSO, p > 0.999; methyl hexanoate vs. DMSO, p > 0.999; butyl acetate vs. DMSO, p > 0.999; pentyl acetate vs. DMSO, p = 0.961; geosmin vs. DMSO, p = 0.749. For geosmin, one data point (black circle in the bar plot) was considered as an outlier and was omitted from analysis. 2 ≤ n ≤ 11. *** p < 0.001, ** p < 0.01, * p < 0.05.

Article Snippet: Full sequences for the reported constructs and plasmid availability information are accessible at Addgene ( https://www.addgene.org ) with the following reference numbers: pcDNA3.1(-)-mRho.V5.mER.hOr47a: #126472; pcDNA3.1(-)-V5.mER.hOr47a: #126473; pcDNA3.1(-)-V5.hOr47a: #126474; pCMV-BI: #126475; pDmelOR: #126476; pDmelOR-mRho.V5.mER.hOr47a: #126478; pDmelOR-mRho.V5.mER.hOr56a: #126479.

Techniques: Expressing, Transfection, Concentration Assay, Construct, Plasmid Preparation